OncoMatch/Clinical Trials/NCT07131319
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Is NCT07131319 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Tislelizumab, Carboplatin, Pemetrexed and Tislelizumab, paclitaxel, Carboplatin for non-small cell lung cancer.
Treatment: Tislelizumab, Carboplatin, Pemetrexed · Tislelizumab, paclitaxel, Carboplatin — The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are: Will spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify